Ann: POSITIVE FDA GUIDANCE FOR COVID-19 CLINICAL PROGRAM, page-100

First 100 Last

Share
Profile

Follow
fishman67

4,215 Posts.

664

31/05/22

10:40

Post #: 61721869
Share

Originally posted by GiddyYup ↑

Batmansdaughter,

Yes please do point out my "misguidance". If you have something worth while saying then just say it. Don't waste time threats in order to shut down commentary that you don't like.

Now I know you have only been following BIT for a short period of time and probably aren't aware of the long history Biotron have running trials with BIT225 against a range of other viruses. You may not have seen the years of promoting the possibilities and trial results for these or the endless announcements about speaking to partners to fund phase 3 trials and commercialization. More importantly you certainly won't have seen the announcements where these programs were de-prioritized because such announcement are never released.

Shareholders and prospective shareholders have to read between the lines to know what Biotron aren't telling us. They always put a positive spin on every announcement so all news is good news. They meet their continuous disclosure obligations usually without providing much detail. Quite simply I don't recall a single "bad news" announcement from Biotron since I have been following them. This isn't a criticism but rather an observation but I guess you need to follow something for more than 6 months to be able to observe long term trends.

By their very nature they need to think positively to do this sort of research and development. Most biotech candidates never make it to market however if their management and staff were not fundamentally optimists following a dream then the world would certainly be a worse place with fewer real world drugs making it to market to treat horrible diseases. Its high risk, high reward stuff and I'm not here to criticize this because I understand why they do what they do and Ive supported it with my money through CRs on numerous occasions over many years.

You may not use the language the same way as I do however when I write "does not guarantee", I don't think its reasonable to transform this into a prediction that something is unlikely or simply won't happen. Please stick to the facts about what I wrote and if you can provide any evidence whatsoever that the trial is "guaranteed" then please provide it.

The fact is I believe the next trial is highly likely but not necessarily imminent. I certainly don't see any guarantees and if history is any guide I won't be holding my breath waiting for it to happen quickly. Funding doesn't appear to be in place and partner deals and always proved illusive. I will celebrate as hard as anybody if they do finally manage to pull a rabbit out of their hat.

We are more than 2 years into Covid and BIT225 which existed a decade prior to Covid still hasn't made it to human trials despite more money and support being thrown at Covid than any event in medical history. Big pharma don't appear to have ever shown any significant interest in BIT225 despite being able to take a controlling stake using the cash down the back of couch in their entry lobby. Investors want to see any sign that this has changed.

My post may seem negative and if you are one of those that prefer to not know the truth about the past and don't want logical analysis to taint your "bottomless glass is overflowing" then thats your right. I have no problem with endless optimism and quite frankly wish I could make a living thinking that way myself. If you don't like logic, history, truth, or other people's opinions based on experience then please help yourself and just ignore it.

I'm sure you are a nice person and I wish you the very best in your investment however it is that you make your decisions.

Expand

Bit225 clinical phase 2A trials were a raging success 2018……slow process to understand the markers, clinical phase 2B trial to shore up those markers we achieved. All the while a Coronavirus pandemic, countries in lockdown etc etc the company has done pretty well under those circumstances and the fact we don’t have the luxury of a big backing. One step closer to lay the cards on the table!!! Pretty embarrassing for all those involved if they come up short lol

BIT Price at posting: 8.6¢ Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

OJC

SPC to merge with Original Juice Co and Nature One Dairy

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

COB

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

There are more pages in this discussion • 373 more messages in this thread...

First 100 Last

Add BIT (ASX) to my watchlist

(20min delay)
Last 2.0¢		Change 0.001(5.26%)		Mkt cap ! $18.04M

Open	High	Low	Value	Volume
1.9¢	2.0¢	1.9¢	$6.191K	315.2K

Buyers (Bids)

No.	Vol.	Price($)
4	963297	1.9¢

Sellers (Offers)

Price($)	Vol.	No.
2.0¢	1734532	5

View Market Depth

No.	Vol.	Price($)
4	963297	0.019
10	1774771	0.018
8	927388	0.017
12	3734154	0.016
9	1155000	0.015

Price($)	Vol.	No.
0.020	1734532	5
0.021	605263	2
0.022	997769	4
0.023	1449422	4
0.024	153949	2

Last trade - 16.10pm 02/10/2024 (20 minute delay)

BIT (ASX) Chart

Ann: POSITIVE FDA GUIDANCE FOR COVID-19 CLINICAL PROGRAM, page-100

SPC to merge with Original Juice Co and Nature One Dairy

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: POSITIVE FDA GUIDANCE FOR COVID-19 CLINICAL PROGRAM, page-100

Top Stories

SPC to merge with Original Juice Co and Nature One Dairy

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News